ट्रेड Vir Biotechnology VIR

VirBiotechnology लाइव चार्ट

उपकरण मूल बातें

Weekly Search
Weekly
Daily
दिनांक बंद करें परिवर्तन (%) परिवर्तित करें खुला उच्च कम

VirBiotechnology news

नवीनतम समाचार

और दिखाएं
Tommy Yap 2025 मई 09, 21:00

Week Ahead: U.S. Inflation Data in Spotlight

Forex Indices
Frances Wang 2025 मई 08, 16:00

What Is Happening to the Bond Market: Bond Market Outlook 2025

Bonds
Frances Wang 2025 मई 08, 16:00

Bond Market News Today: Alphabet (GOOGL) Back to Corporate Bond Market

Bonds
Frances Wang 2025 मई 08, 16:00

Tariffs News Update: How Trump’s Policies Affect Bond Market?

Bonds
Tommy Yap 2025 मई 08, 16:00

Morning Note: Dollar Climbs on Trade Winds; BTC Soars; ECB's Dovish Tone

Morning Note Forex Cryptocurrencies
Frances Wang 2025 मई 07, 16:00

Stock Market Today: Dow Jones Up, Nvidia stock fluctuates, Nasdaq Rises

Stocks Indices NVDA
Tommy Yap 2025 मई 07, 16:00

Morning Note: BoE Rate Cut?, US Jobs, Toyota Earnings Today

Morning Note USD GBP
Frances Wang 2025 मई 06, 16:00

Trending forex pairs: EUR/USD Fluctuates, USD/TWD Drops, AUD/JPY Rises

Forex

जानकारी

स्प्रेड

0.05

स्प्रेड (%)

0.9785 %

लीवरेज

1:10

ओवरनाइट ब्याज विक्रय

-0.0597 %

overnight_interest_sell

-0.0292 %

मुद्रा

USD

ट्रेडिंग घंटे

बाज़ार बंद है

सोमवार

13:31 - 19:59

मंगवार

13:31-19:59

बुधवार

13:31-19:59

गुरुवार

13:31-19:59

शुक्रवार

13:31-19:59

विश्लेषण और सांख्यिकी

खुला

---

पिछला बंद

---

52 सप्ताह उच्च/निम्न्च

--- – ---

बाज़ार आकार

702055424

बकाया शेयर

138064000

प्राप्ति की तिथि (आगे)

0000-00-00

लाभांश आय 

पूर्व-लाभांश तिथि

अग्रिम वार्षिक लाभांश दर 

0

अग्रिम वार्षिक लाभांश आय

0

EPS

-4.23

इस उपकरण के बारे में अधिक जानें

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

संबंधित उपकरण

संपत्ति
बेचें
खरीदें
(%) परिवर्तित करें
view_all_instruments

latest_education_articles

और दिखाएं
Trustpilot